|1.||Blennow, Kaj: 7 articles (12/2015 - 11/2010)|
|2.||Zetterberg, Henrik: 7 articles (12/2015 - 11/2010)|
|3.||Andreasson, Ulf: 5 articles (12/2015 - 01/2015)|
|4.||Portelius, Erik: 5 articles (12/2015 - 01/2015)|
|5.||Kvartsberg, Hlin: 3 articles (10/2015 - 01/2015)|
|6.||Hansson, Oskar: 3 articles (10/2015 - 11/2010)|
|7.||Minthon, Lennart: 3 articles (10/2015 - 11/2010)|
|8.||Owen, Michael J: 3 articles (10/2011 - 01/2011)|
|9.||O'Donovan, Michael C: 3 articles (10/2011 - 01/2011)|
|10.||Rujescu, Dan: 3 articles (10/2011 - 08/2009)|
|1.||Schizophrenia (Dementia Praecox)
10/01/2013 - "In this study, we investigated the influences of neurogranin genotypes (rs12807809 and rs12278912), haplotypes and diplotypes and genetic variant-diagnosis interactions on intellectual ability in 414 Japanese patients with schizophrenia and healthy subjects. "
07/01/2011 - "A recent study reported a genome-wide significant association between schizophrenia and rs12807809-a SNP located approximately 3 kbp upstream of the neurogranin gene (NRGN). "
10/01/2013 - "Genome-wide association studies have reported an association between schizophrenia and rs12807809 of the neurogranin (NRGN) gene. "
01/01/2013 - "Although the genome wide supported psychosis susceptibility neurogranin (NRGN) gene is expressed in human brains, it is unclear how it impacts brain morphology in schizophrenia. "
01/01/2013 - "Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia."
|2.||Alzheimer Disease (Alzheimer's Disease)
12/01/2015 - "C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease."
11/01/2015 - "Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease."
11/01/2015 - "Neurogranin Levels in Cerebrospinal Fluid: A New Addition to the Alzheimer Disease Diagnostic Toolbox."
11/01/2015 - "Furthermore, within the progressive mild cognitive impairment group, elevated cerebrospinal fluid neurogranin levels were associated with accelerated deterioration in Alzheimer's Disease Assessment Scale-cognitive subscale (β = 0.0017, P = 0.01). "
11/01/2015 - "In the mild cognitive impairment group, high baseline cerebrospinal fluid neurogranin levels predicted cognitive decline as reflected by decreased Mini-Mental State Examination (P < 0.001) and increased Alzheimer's Disease Assessment Scale-cognitive subscale (P < 0.001) scores at clinical follow-up. "
|3.||Brain Injuries (Brain Injury)
09/01/2015 - "Serum neurogranin measurement as a biomarker of acute traumatic brain injury."
02/01/2000 - "The brain contusions showed loss of both MAP2- and neurogranin immunoreactivity at the site of the lesion. "
11/01/2015 - "Here, we tested the performance of cerebrospinal fluid neurogranin to predict cognitive decline and brain injury in the Alzheimer's Disease Neuroimaging Initiative study. "
|4.||Parkinson Disease (Parkinson's Disease)
12/03/2014 - "Additionally, phosphorylated neurogranin levels were also decreased in the human superior temporal cortex in patients diagnosed with Parkinson's disease and patients diagnosed with dementia with Lewy bodies. "
12/03/2014 - "Coimmunoprecipitation studies in the superior temporal cortex in humans confirmed interaction between α-synuclein and neurogranin, and decreased interaction between α-synuclein and neurogranin was noticed in patients diagnosed with Parkinson's disease when compared to normal control brains. "
12/03/2014 - "Here, we show for the first time that neurogranin binds to α-synuclein in the human cortex, and this interaction decreases in Parkinson's disease along with the phosphorylation of neurogranin, a molecular process thought to be involved in learning and memory. "
12/03/2014 - "Neurons expressing neurogranin in the cortex degenerate in late stages of Parkinson's disease with widespread α-synuclein pathology. "
12/03/2014 - "Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease."
12/01/2015 - "Using an in-house designed prototype enzyme-linked immunosorbent assay (ELISA) targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n = 29) versus patients experiencing MCI, or dementia, due to AD (in total n = 59). "
01/01/2015 - "CSF levels of neurogranin and YKL-40 did not differ between MCI not due to AD and non-AD dementias. "
01/01/2015 - "Patients with dementia or MCI due to AD showed elevated levels of CSF neurogranin (p < 0.001 for AD-D and p < 0.05 for MCI-AD) and YKL-40 (p < 0.05 for AD-D and p = 0.15 for MCI-AD) compared to mildly cognitively impaired subjects not diagnosed with AD. "
01/01/2015 - "CSF samples from 95 individuals including 39 patients with AD dementia (AD-D), 13 with mild cognitive impairment (MCI) due to AD (MCI-AD), 29 with MCI not due to AD (MCI-o) and 14 patients with non-AD dementias (non-AD-D) were analyzed for neurogranin and YKL-40. "
11/01/2015 - "Cerebrospinal fluid neurogranin was increased in patients with Alzheimer's disease dementia (P < 0.001), progressive mild cognitive impairment (P < 0.001) and stable mild cognitive impairment (P < 0.05) compared with controls, and in Alzheimer's disease dementia (P < 0.01) and progressive mild cognitive impairment (P < 0.05) compared with stable mild cognitive impairment. "
|2.||Transcription Factors (Transcription Factor)
|3.||Tretinoin (Retinoic Acid)
|4.||Messenger RNA (mRNA)
|5.||Calmodulin (Calcium-Dependent Activator Protein)
|6.||Calcium-Calmodulin-Dependent Protein Kinase Type 2
|8.||Brain-Derived Neurotrophic Factor (BDNF)
|9.||Cytoplasmic and Nuclear Receptors (Nuclear Receptors)